Ventria Bioscience Appoints Margaret Glick, Ph.D., CPA as Vice President of Finance

Ventria Bioscience Appoints Margaret Glick, Ph.D., CPA as Vice President of Finance

FORT COLLINS, Colo.--(BUSINESS WIRE)--Ventria Bioscience today announced that Margaret B. Glick, Ph.D., CPA has been appointed as the company's new vice president of finance. Dr. Glick will oversee all financial and related administrative functions for the company.

"Maggie comes to Ventria Bioscience with expertise in private and public corporate finance as well as organizational development—a combination that will provide fundamental value to the company as we pursue our long-term strategic goals"
"Maggie comes to Ventria Bioscience with expertise in private and public corporate finance as well as organizational development—a combination that will provide fundamental value to the company as we pursue our long-term strategic goals," said Scott Deeter, president and chief executive officer of Ventria Bioscience.

Before joining Ventria Bioscience, Dr. Glick served as chief financial officer and vice president of finance for Five Rivers Ranch Cattle Feeding LLC (now JBS Five Rivers Cattle) a $1.2 billion joint venture between Continental Grain Company and Smithfield Foods. She also served as accounting officer at Colorado State University's College of Veterinary Medicine and Biomedical Sciences, and was an assistant professor of organizational development, performance, and change. Dr. Glick previously held positions as controller at Enginuity Engineering Solutions LLC; accounting manager at GE Global Controls Services; and controller and chief accounting officer at Basin Exploration and Dakota Mining Company, two publicly held mining and exploration companies. Dr. Glick graduated from Colorado State University with a master's degree in accounting and a doctorate in organizational development, and holds an active Certified Public Accountant (CPA) license and Senior Professional in Human Resources (SPHR) certification.

About Ventria Bioscience

Ventria Bioscience develops, manufactures, and markets biotherapeutics and bioreagents. Ventria Bioscience's patented ExpressTec biomanufacturing technology enables the development of new and cost-effective biologic products. For more information, visit www.Ventria.com.

Contacts

Ventria Bioscience
Jeanne Berkowitz, +1-720-684-6673
[email protected]

Suggested Articles

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Gilead names Dickinson to CFO role; MedImmune CSO Herbst nabs CSO job at Pyxis; Checkmate picks up Wooldridge for CMO.

The readout is a key moment in the history of the drug and Mirati, shares in which have soared in the updraft created by data on Amgen’s rival asset.